Case-Based Roundtable Meetings Spotlight: March 1, 2023
Poll: How Would You Treat a Patient With NSCLC and an EGFR Exon 20 Insertion Mutation?
March 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joel Neal, MD, PhD, discussed what options physicians would choose when treating a patient with non–small cell lung cancer who tested positive for an EGFR exon 20 insertion.
Campbell Discusses Choices for Patients With Favorable- and Intermediate-Risk RCC
March 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew T. Campbell, MD, MS, discussed data supporting frontline combination therapies for patients with favorable- and intermediate-risk clear cell renal cell carcinoma.
Roundtable Discussion: Ailawadhi Compares Therapies in Newly Diagnosed Multiple Myeloma
March 7th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sikander Ailawadhi, MD, discussed with participants the choice of regimen for a patient with transplant-eligible newly diagnosed multiple myeloma.
Roundtable Discussion: Voss Looks at Integrating New Approaches in Clear Cell RCC Treatment
February 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Martin H. Voss, MD, discussed with participants their goals and approaches when considering third-line therapy for patients with advanced clear cell renal cell carcinoma.
